Summaries and analysis of industry press releases
Redemplo (plozasiran) cleared for familial chylomicronemia syndrome at $60,000 annual price—ten times lower than competitor Arrowhead Pharmaceuticals achieved a transformational
Biotech prepares FDA submission despite failing key pain crisis endpoint; shares plummet 47% on data release Agios Pharmaceuticals announced mixed
Agios Pharmaceuticals recently faced a substantial decline in its stock value following the announcement of mixed results from a Phase
BIOPHARMA EXECUTIVE INTELLIGENCE BRIEFING November 19, 2025 Headline Findings: Merck has announced a definitive agreement to acquire Cidara Therapeutics for
On November 18, 2025, Arrowhead Pharmaceuticals made a historic move by receiving the FDA approval for Redemplo, a groundbreaking treatment
In a bold move aimed at revitalizing American pharmaceutical research, FDA Commissioner Marty Makary has put forth a proposal to
The recent announcement from the White House about a new trade deal, aimed at capping tariffs on pharmaceutical imports from
In a bold move that signals its commitment to advancing cancer treatment, Johnson & Johnson (J&J) has announced a $3.05
On November 14, 2025, the U.S. Food and Drug Administration (FDA) made significant updates to the label of Sarepta Therapeutics’
In a significant shift in the biopharmaceutical landscape, Bristol Myers Squibb and Johnson & Johnson have announced the early termination
In a significant move that underscores the evolving landscape of cancer drug development, Day One Biopharmaceuticals has announced the acquisition
The landscape of cancer treatment is evolving, especially for patients battling acute myeloid leukemia (AML), a notoriously aggressive cancer that
In a significant move, President Donald Trump recently signed a short-term government funding bill, effectively ending the longest shutdown in
In recent weeks, the U.S. Food and Drug Administration (FDA) has witnessed significant leadership changes, particularly with the appointment of
In recent years, China’s biotechnology sector has undergone a remarkable transformation, shedding its image as merely a follower in the
The biopharmaceutical landscape is undergoing a significant transformation with the recent appointment of Richard Pazdur as the new director of
The landscape of cancer treatment has evolved dramatically over the past decade, particularly with the introduction of checkpoint inhibitors that
The landscape of cancer treatment has evolved dramatically over the past decade, yet one glaring issue remains: the cost of
In a significant legal development, a federal jury has acquitted Novo Nordisk of allegations claiming fraud in the promotion of
Cogent Biosciences is making waves in the biopharmaceutical industry following the remarkable success of its recent Phase 3 clinical trial